Theranexus SA
ALTHX.PADrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
THN102 300/3 | Phase 2 | Narcolepsy | - | - |
THN102 Dosage A | Phase 2 | Parkinson Disease | - | - |
Frequently asked questions
What is in Theranexus SA's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Theranexus SA's (ALTHX.PA) pipeline across Phase 2. Its lead program is THN102 300/3 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Theranexus SA's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Theranexus SA (ALTHX.PA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ALTHX.PA biotech catalysts?→
Add ALTHX.PA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Theranexus SA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.